Given the current literature, FDA approval of IFN-α to treat various types of cancer [97], and recent literature supporting the role of type I IFN to promote anti-tumor immune responses, the transgene IFN-β was engineered into VSV to enhance the safety and immunogenicity of the virus. The gene discussed is IFNA1; the disease is neoplasm.